{'fraction_non_alphanumeric': 0.014388489208633094, 'fraction_numerical': 0.003083247687564234, 'mean_word_length': 6.161764705882353, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
P15‐8: Dasatinib induced pulmonary arterial hypertension and pleural effusion in post allogenic stem cell transplant cml patient

Though Dasatinib is a second-generation tyrosine kinase inhibitor used for the first line therapy of CML, it is associated with the risk of pulmonary hypertension and pleural effusion. Pleural effusion due to Dasatinib is often reversible unlike pulmonary hypertension. Asymptomatic pleural effusion warrants only conservative management and regular follow up. For symptomatic effusions, dose reduction or dose interruption is recommended. Dasatinib induced pulmonary hypertension warrants drug discontinuation, treatment with an alternative TKI and upfront combination therapy with vasodilators if symptoms persist. We present a patient of chronic myeloid leukemia (blast crisis) post allogenic stem cell transplant in molecular response that developed bilateral pleural effusion and pulmonary hypertension following treatment with Dasatinib.